Rezultati pretraživanja
  1. Cowen maintains Buy rating with $66 price target. ACADIA Pharmaceuticals (NASDAQ:ACAD) Stock Rating Reaffirmed by Cowen – Riverton Roll

  2. prije 7 sati

    and almost all other biotech breaking out today. Pretty much the only good value plays left.

  3. prije 7 sati

    There are very few mid-cap biotech companies that can boast the level of institutional commitment seen in :

  4. : New SEC Filing for ACAD: Form SC 13G/A (No. 0000834237-20-004587):

  5. prije 11 sati

    alerted for an option play...looks like the best way to play this one

  6. prije 13 sati
  7. 4. velj

    Acadia Pharmaceuticals: Undervalued And Ripe For A Major Run-Up

  8. 4. velj

    Baml investor call with ACAD mgt to discuss ongoing Nuplazid sales and pipeline in DRP, MDD and Rett. MGT provided more color on expectations from pre-sNDA meeting&launch preparation in DRP. expect MDD data from US Clarity-2 study in 4Q20&Rett data of trofinetide in 2021.

  9. 3. velj

    rounding out for a new base, pivot holds

    Prikaži ovu nit
  10. 31. sij
    Prikaži ovu nit
  11. 31. sij
  12. 31. sij

    there is a very long list of stocks down over 25% from highs in last few weeks just in the A's

  13. 31. sij

    ACADIA Pharmaceuticals Target of Unusually Large Options Trading

  14. 30. sij
  15. 30. sij

    Healthcare Opportunities: "biotech ETF fighting at very round 90 number. records second worst weekly return last week in over a year. well in bear market mode off 23% from most recent 52 week highs."

  16. 29. sij

    The editor of MTSL believes Acadia "has attracted the attention of Big Pharma acquirers" because of impending label expansion for Nuplazid:

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.